Telogen effluvium

Last updated
Telogen effluvium
Malnurished Afghan Child.jpg
An Afghan child displaying hair loss due to severe malnutrition
Specialty Dermatology   OOjs UI icon edit-ltr-progressive.svg

Telogen effluvium is a scalp disorder characterized by the thinning or shedding of hair resulting from the early entry of hair in the telogen phase (the resting phase of the hair follicle). [1] [2] [3] It is in this phase that telogen hairs begin to shed at an increased rate, where normally the approximate rate of hair loss (having no effect on one's appearance) is 125 hairs per day. [4]

Contents

There are 5 potential alterations in the hair cycle that could lead to this shedding: immediate anagen release, delayed anagen release, short anagen syndrome, immediate telogen release, and delayed telogen release. [4] [5]

Emotional or physiological stress may result in an alteration of the normal hair cycle and cause the disorder, with potential causes including eating disorders, crash diets, pregnancy and childbirth, chronic illness, major surgery, anemia, severe emotional disorders, hypothyroidism, and drugs. [1] [7]

Diagnostic tests, which may be performed to verify the diagnosis, include a trichogram, trichoscopy [8] and biopsy. [7] Effluvium can present with similar appearance to alopecia totalis, with further distinction by clinical course, microscopic examination of plucked follicles, or biopsy of the scalp. [9] Histology would show telogen hair follicles in the dermis with minimal inflammation in effluvium, and dense peribulbar lymphocytic infiltrate in alopecia totalis. [10]

Vitamin D levels may also play a role in the normal hair cycle. [11]

Many new cosmetic treatments have been reported, including Stemoxydine, Nioxin, minoxidil, and a leave-on technology combination: caffeine, niacinamide, panthenol, dimethicone, and an acrylate polymer (CNPDA). This treatment has shown to increase the diameter of existing, individual scalp hair fibres by 2–5 μm, yielding a significant increase of approximately 10% in the cross-sectional area of each hair. Additionally, CNPDA-thickened hairs also demonstrate altered mechanical properties of thicker fibres; increased suppleness/pliability, and increased ability to withstand force without breaking. [12]

See also

Related Research Articles

<span class="mw-page-title-main">Alopecia areata</span> Medical condition

Alopecia areata, also known as spot baldness, is a condition in which hair is lost from some or all areas of the body. It often results in a few bald spots on the scalp, each about the size of a coin. Psychological stress and illness are possible factors in bringing on alopecia areata in individuals at risk, but in most cases there is no obvious trigger. People are generally otherwise healthy. In a few cases, all the hair on the scalp is lost, or all body hair is lost. Hair loss can be permanent, or temporary.

<span class="mw-page-title-main">Hair loss</span> Loss of hair from the head or body

Hair loss, also known as alopecia or baldness, refers to a loss of hair from part of the head or body. Typically at least the head is involved. The severity of hair loss can vary from a small area to the entire body. Inflammation or scarring is not usually present. Hair loss in some people causes psychological distress.

<span class="mw-page-title-main">Hair follicle</span> Organ found in mammalian skin

The hair follicle is an organ found in mammalian skin. It resides in the dermal layer of the skin and is made up of 20 different cell types, each with distinct functions. The hair follicle regulates hair growth via a complex interaction between hormones, neuropeptides, and immune cells. This complex interaction induces the hair follicle to produce different types of hair as seen on different parts of the body. For example, terminal hairs grow on the scalp and lanugo hairs are seen covering the bodies of fetuses in the uterus and in some newborn babies. The process of hair growth occurs in distinct sequential stages: anagen is the active growth phase, catagen is the regression of the hair follicle phase, telogen is the resting stage, exogen is the active shedding of hair phase and kenogen is the phase between the empty hair follicle and the growth of new hair.

<span class="mw-page-title-main">Alopecia universalis</span> Medical condition

Alopecia universalis(AU), also known as alopecia areata universalis, is a medical condition involving the loss of all body hair, including eyebrows, eyelashes, chest hair, armpit hair, and pubic hair. It is the most severe form of alopecia areata (AA). People with the condition are usually healthy and have no other symptoms and a normal life expectancy.

The management of hair loss, includes prevention and treatment of alopecia, baldness, and hair thinning, and regrowth of hair.

Trichology is the study of the hair and scalp. The term derives from Ancient Greek θρίξ (thríx), "hair" and -λογία -logia. In most jurisdictions the title of a trichologist, not the field of trichology, is considered a para-medical discipline.

<span class="mw-page-title-main">Pattern hair loss</span> Medical condition

Pattern hair loss is a hair loss condition that primarily affects the top and front of the scalp. In male-pattern hair loss (MPHL), the hair loss typically presents itself as either a receding front hairline, loss of hair on the crown and vertex of the scalp, or a combination of both. Female-pattern hair loss (FPHL) typically presents as a diffuse thinning of the hair across the entire scalp.

Ophiasis is a form of alopecia areata characterized by the loss of hair in the shape of a wave at the circumference of the head.

Madarosis is a condition that results in the loss of eyelashes, and sometimes eyebrows. The term "madarosis" is derived from the ancient Greek "madaros", meaning "bald". It originally was a disease of only losing eyelashes but it currently is the loss of both eyelashes and eyebrows. Eyebrows and eyelashes are both important in the prevention of bacteria and other foreign objects from entering the eye. A majority of patients with madarosis have leprosy, and it was reported that 76% of patients with varying types of leprosy had madarosis.

Anagen effluvium is the pathologic loss of anagen or growth-phase hairs. Classically, it is caused by radiation therapy to the head and systemic chemotherapy, especially with alkylating agents.

<span class="mw-page-title-main">Loose anagen syndrome</span> Medical condition

Loose anagen syndrome, also known as loose anagen hair syndrome, is a hair disorder related to dermatology. It is characterised by the easy and pain free detachment of anagen staged hairs from the scalp. This hair condition can be spontaneous or genetically inherited.

Scarring hair loss, also known as cicatricial alopecia, is the loss of hair which is accompanied with scarring. This is in contrast to non scarring hair loss.

Non scarring hair loss, also known as noncicatricial alopecia is the loss of hair without any scarring being present. There is typically little inflammation and irritation, but hair loss is significant. This is in contrast to scarring hair loss during which hair follicles are replaced with scar tissue as a result of inflammation. Hair loss may be spread throughout the scalp (diffuse) or at certain spots (focal). The loss may be sudden or gradual with accompanying stress.

<span class="mw-page-title-main">Trichoscopy</span> Medical diagnostic method

Trichoscopy is a method of hair and scalp evaluation and is used for diagnosing hair and scalp diseases. The method is based on dermoscopy. In trichoscopy hair and scalp structures may be visualized at many-fold magnification. Currently magnifications ranging from 10-fold to 70-fold are most popular in research and clinical practice.

Antonella Tosti is an Italian physician and scientist with major contributions in the field of dermatology, including developing dermoscopy for the diagnosis and care of hair diseases, a world recognized expert in hair disorders. Her contributions to knowledge about nails include research about videodermoscopy of the hyponychium and the nail plate.

<span class="mw-page-title-main">Frontal fibrosing alopecia</span> Medical condition

Frontal fibrosing alopecia is the frontotemporal hairline recession and eyebrow loss in postmenopausal women that is associated with perifollicular erythema, especially along the hairline. It is considered to be a clinical variant of lichen planopilaris.

The growth of human hair occurs everywhere on the body except for the soles of the feet, the palms of the hands, the inside of the mouth, the lips, the backs of the ears, some external genital areas, the navel, and, apart from eyelashes, the eyelids. Hair is a stratified squamous keratinized epithelium made of multi-layered flat cells whose rope-like filaments provide structure and strength to the hair shaft. The protein called keratin makes up hair and stimulates hair growth. Hair follows a specific growth cycle with three distinct and concurrent phases: anagen, catagen, and telogen. Each phase has specific characteristics that determine the length of the hair.

Short anagen syndrome is a condition where hair does not grow beyond a short length, due to an unusually short duration of active hair growth. Most cases are associated with fine blond hair.

Frictional alopecia is the loss of hair that is caused by rubbing of the hair, follicles, or skin around the follicle. The most typical example of this is the loss of ankle hair among people who wear socks constantly for years. The hair may not grow back even years after the source of friction has ended.

<span class="mw-page-title-main">Minoxidil sulfate</span> Chemical compound

Minoxidil sulfate, also known as minoxidil sulfate ester or minoxidil N-O-sulfate, is an active metabolite of minoxidil and is the active form of this agent. Minoxidil acts as a prodrug of minoxidil sulfate. Minoxidil sulfate is formed from minoxidil via sulfotransferase enzymes, with the predominant enzyme responsible, at least in hair follicles, being SULT1A1. Minoxidil sulfate acts as a potassium channel opener, among other actions, and has vasodilating, hypotensive, and trichogenic or hypertrichotic effects. Its mechanism of action in terms of hair growth is still unknown, although multiple potential mechanisms have been implicated.

References

  1. 1 2 Marks, James G; Miller, Jeffery (2006). Lookingbill and Marks' Principles of Dermatology (4th ed.). Elsevier Inc. Page 263. ISBN   1-4160-3185-5.
  2. James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology. (10th ed.). Saunders. ISBN   0-7216-2921-0.
  3. Asghar, Fahham; Shamim, Nazia; Farooque, Umar; Sheikh, Haris; Aqeel, Ramsha (2020). "Telogen Effluvium: A Review of the Literature". Cureus . 12 (5): e8320. doi: 10.7759/cureus.8320 . PMC   7320655 . PMID   32607303.
  4. 1 2 3 Khan Mohammad Beigi, Pooya (2018). "Introduction". In Khan Mohammad Beigi, Pooya (ed.). Alopecia Areata: A Clinician's Guide. Springer International Publishing. pp. 3–5. doi:10.1007/978-3-319-72134-7_1. ISBN   9783319721347.
  5. 1 2 Liyanage, Deepa; Sinclair, Rodney (2016-03-25). "Telogen Effluvium". Cosmetics. 3 (2): 13. doi: 10.3390/cosmetics3020013 . ISSN   2079-9284.
  6. Grover, Chander; Khurana, Ananta (2013). "Telogen effluvium". Indian Journal of Dermatology, Venereology and Leprology. 79 (5): 591–603. doi: 10.4103/0378-6323.116731 . ISSN   0378-6323. PMID   23974577.
  7. 1 2 Freedberg, et al. (2003). Fitzpatrick's Dermatology in General Medicine. (6th ed.). McGraw-Hill. ISBN   0-07-138076-0.
  8. Rudnicka L, Olszewska M, Rakowska A, Kowalska-Oledzka E, Slowinska M (2008). "Trichoscopy: a new method for diagnosing hair loss". J Drugs Dermatol. 7 (7): 651–654. PMID   18664157.
  9. Werner, B.; Mulinari-Brenner, F. (2012). "Clinical and histological challenge in the differential diagnosis of diffuse alopecia: Female androgenetic alopecia, telogen effluvium and alopecia areata – part II". Anais Brasileiros de Dermatologia. 87 (6): 884–890. doi:10.1590/S0365-05962012000600010. PMC   3699921 . PMID   23197208.
  10. Alkhalifah, A. (2012). "Alopecia Areata Update". Dermatologic Clinics. 31 (1): 93–108. doi:10.1016/j.det.2012.08.010. PMID   23159179.
  11. Amor KT, Rashid RM, Mirmirani P (2010). "Does D matter? The role of vitamin D in hair disorders and hair follicle cycling". Dermatol. Online J. 16 (2): 3. doi:10.5070/D38S34P6B7. PMID   20178699.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  12. Davis, M.G.; Thomas, J.H.; van de Velde, S.; Boissy, Y.; Dawson, T.L.; Iveson, R.; Sutton, K. (December 2011). "A novel cosmetic approach to treat thinning hair". British Journal of Dermatology. 165: 24–30. doi:10.1111/j.1365-2133.2011.10633.x. ISSN   0007-0963. PMID   22171682. S2CID   21918537.